Morning Read: Meet President Obama’s precision medicine czar
Also, Perrigo responds to Mylan, changes in the FDA's transparency, and Eli Lilly's Jardiance pays dividends.
Morning Read: GE Healthcare remains part of GE, GOP candidates avoid Obamacare
Also, what did GSK know on Seroxat, big move by MobiHealthNews and Aerie Pharmaceuticals has a breakthrough.
presented by
The Top 6 Best Analytics Tools for Health Care Revenue in 2025
Finding the best analytics tools for health care revenue management can revolutionize operational processes. Compare the leading software options to discover helpful team resources.
Morning Read: America hates Big Pharma again
Plus, poverty said to be a factor in readmissions, CDC has permanent associate director of lab safety and women called clueless about women's health.
Morning Read: EMR vendor grades are in (it doesn’t look good)
Also, the Mylan-Perrigo hostile takeover is underway, Medtronic gets an FDA approval and new population health innovations are popping up throughout the country.
Morning Read: Shire coming back at Baxalta, more reasons to ogle Google in healthcare
Plus, another life science IPO in London, a shifting (and slowing) of Obamacare dollars and much more
Morning Read: Actelion working on $2.5B deal to acquire ZS Pharma
Actelion is considering a move to acquire ZS Pharma in a deal valued at $2.5 billion.
presented by
How to Optimize Your Phlebotomy Setup for Efficient Patient Care
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
Morning Read: Joslin Diabetes Center CEO forced to resign, Mallinckrodt Pharma subsidiaries want to acquire TGG Medical in $750M deal
Joslin Diabetes Center CEO John Brooks III, has been forced out after four years with the business, two Mallinckrodt Pharmaceuticals subsidiaries are preparing to offer $750 million in unsecured notes to acquire TGG Medical Solutions
Morning Read: GlaxoSmithKline’s new COPD inhaler failed, half of Americans have diabetes or pre-diabetes
GlaxoSmithKline's new COPD drug unfortunately failed to extend life in those involved with a major clinical trial, and 50 percent of Americans have diabetes or pre-diabetes, putting them at risk for developing the chronic condition.
Morning Read: A big month for Aetna’s acquisition hopes
Also, learn about an increasingly higher profile for MedCity CONVERGE alum Dr. Vivian S. Lee.
Morning Read: Will this Chantix study move the needle for the FDA?
And a great tidbit on a biological illustration class.
presented by
The Top-Rated Orthopedic Surgery Centers in the Houston Area and Beyond
Discover Houston's best orthopedic surgery centers and what features — from personalized treatment plans to rehabilitation services — make these top providers stand out in their industry.
Morning Read: Bill & Melinda Gates Foundation grants $9.6M to reduce newborn mortality in Ethiopia
The Institute for Healthcare Improvement announced that it received a $9.6M grant from the Bill & Melinda Gates Foundation to reduce newborn mortality in Ethiopia.
Morning Read: UAW proposes healthcare Co-Op, Novartis launches biosimilar drug in U.S. to boost white blood cell count
United Auto Workers Union is floating the idea of a healthcare Co-Op to the three largest car makers, Novartis launched its first biosimilar drug to improve white blood cell counts in cancer and rheumatoid arthritis patients.
Morning Read: AstraZeneca deal for psoriasis drug valued at up to $445M
AstraZeneca entered into a licensing agreement, valued at up to $445 million, for its experimental psoriasis drug.
Morning Read: Bristol-Myers Squibb will acquire immunotherapy group Promedior for $1.25B
Bristol-Myers Squibb has paid for the right to acquire US clinical stage immunotherapy group Promedior in a deal valued at up to $1.25 billion, securing access to the firm’s fibrotic disease candidates.
Morning Read: Renowned neurologist and author Oliver Sacks dies, Amicus acquires Scioderm in a $229M deal
Renowned neurologist and author Oliver Sacks has died of cancer at the age of 82, Amicus Therapeutics has acquired a drug to treat a rare skin disorder through its purchase of Scioderm in a $229 million deal.